WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- In a new post-hoc analysis presented for the first time at the American Diabetes Association (ADA) 70 th Annual Scientific Sessions, significantly more ...
Merck & Co., after settling with nearly two dozen drugmakers aiming to launch generics of its blockbuster Type 2 diabetes med Januvia, has successfully parried a Viatris patent assault in court. A U.S ...
Diabetes drugs including Merck & Co.’s Januvia, Bristol-Myers Squibb Co.’s Byetta and Novo Nordisk A/S’s Victoza are being scrutinized by U.S. regulators for a possible link to pre-cancerous findings.
If a person has a Part D prescription drug plan, they must first pay their deductible. As private insurers administer these plans, out-of-pocket costs and drug availability may vary. In 2025, the ...
Merck’s (NYSE:MRK) Alimentary & Metabolism drugs account for around 10% of the company’s value, according to our estimates. The key drugs in this segment are Januvia and Janumet. We don’t expect any ...
Merck patent covers forms of Januvia, Janumet Generic drugmaker Mylan loses bid to cancel patent (Reuters) - A Merck Sharp & Dohme Corp patent related to its diabetes drugs Januvia and Janumet is ...
Aug 9 (Reuters) - The U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck's (MRK.N), opens new tab diabetes drugs Januvia and Janumet, were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback